We describe a case of cholangiocarcinoma in a young woman, who presented with cholestatic jaundice following oral contraceptive ingestion. Following diagnostic laparotomy she received intra-arterial 'lipiodolized' chemotherapy. Intravenous mitozantrone was given for 2 years and she is asymptomatic, with computed tomographic evidence of tumour response, 27 months after diagnosis. We suggest that this form of treatment is of value for cholangiocarcinoma.
Introduction
Whilst there have been frequent reports of hepatocellular carcinoma in users of oral contraceptives, cholangiocarcinoma is rare. We describe such a case, which responded to 'T'-tube drainage and chemotherapy by intra-arterial and intravenous There were no complications following the procedure and she was discharged 5 days later with the 'T'-tube still in place but spigotted.
Subsequently she received mitozantrone 12 mg/M2 3-weekly for 2 years. Serial abdominal CT scans at 3, 6, 12, 18 and 24 months have revealed progressive reduction, ofmore than 50%, in the size ofthe original intrahepatic abnormalities and low attenuation of the tumour mass consistent with complete necrosis. She remains asymptomatic 27 months after laparotomy with her 'T'-tube in situ and has enjoyed a normal lifestyle since commencing chemotherapy. In March oral contraceptive users.2 3' 4 Ten cases of cholangiocarcinoma have been reported,2 4',5 and six cases of mixed cholangiocarcinoma and hepatocellular carcinoma.2'3 However, the incidence of cholangiocarcinoma is low in women of reproductive years and a causal relationship with oral contraceptive use is difficult to demonstrate.
Following palliative 'T'-tube drainage our patient had a single dose of intra-arterial doxorubicin administered in lipiodol and urografin. This method ('lipiodolized' chemotherapy) has resulted in high tissue levels of doxorubicin in hepatoma with much lower levels in liver parenchyma after 16 days, giving an equivalent effect to that of prolonged intra-arterial infusion, without its risks. Lipiodol may also cause embolization of tumour as necrosis followed its use in hepatomas and 'lipiodolized' treatment was effective in producing tumour shrinkage before surgery in 10 of 13 hepatomas. 6 The 27-month asymptomatic survival ofthis patient who had an unresectable tumour exceeds the median survival ofunder one year reported for similar patients who had palliative bypass for drainage7 and indeed compares favourably with results reported following radical resection.8 This is unlikely to be due to withdrawal of hormone support from a hormone dependent tumour since other cases in the literature have not regressed following oral contraceptive withdrawal. The relative contributions of the initial intraarterial therapy and the later prolonged intravenous chemotherapy to tumour regression are difficult to elucidate. Response of cholangiocarcinoma to any therapy would be expected to be slow in view of the known slow cell turnover in these tumours and the delayed regression over two years could be attributed to either or both modalities of treatment.
We emphasize the significance of oral contraceptive ingestion in young women who present with cholestasis and the importance of full investigations of such patients. In this case 'lipiodolized' intra-arterial chemotherapy appears to have been efficacious and we suggest that its value in the treatment ofcholangiocarcinoma is worthy of further study. 
